Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer

Clinical Breast Cancer

Volumn 6, Issue 6, 2006, Pages 505-510

  O'Shaughnessy, Joyce A ^a   Pluenneke, Robert ^a   Sternberg, Jack ^a   Khandelwal, Pankaj ^a   Ilegbodu, Des ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Cytotoxic agents; Dose dense therapy; Neutropenia; Taxanes

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; INCIDENCE; INFECTION; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

EID: 33645638843     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.003     Document Type: Article

References (27)

1. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731-2736.
2. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341-2354.
3. Jones S, Erban J, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2003; 82(suppl 1):S9 (Abstract #10).
4. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17:1413-1424.
5. Sjöström J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194-1201.
6. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 1997; 24(suppl 13):S13-11-S13-18.
7. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol 2004; 23:5 (Abstract #510).
8. Hainsworth JD, Burris HA III, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16:2164-2168.
9. Loeffler TM, Droege C, Hausamen TU. Dose-dense weekly docetaxel (Taxotere®) in metastatic breast cancer. Breast Cancer Res Treat 1999; 57:125 (Abstract #527).
10. Scholz U, Lück HJ, Rittershaus A, et al. Weekly docetaxel treatment in metastatic breast cancer: a phase I/II study. Breast Cancer Res Treat 1998; 50:262 (Abstract #228).
11. Georgoulias V, Kourousis C, Androulakis N, et al. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results. Semin Oncol 1997; 24(suppl 14):S14-S25.
12. Laufman L, Spiridonidis C, Carman L, et al. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (pts) with metastatic breast cancer (MBC): a phase II study. Proc Am Soc Clin Oncol 2000; 19:106a (Abstract #408).
13. Brugnatelli S, Danova M, De Bella MT, et al. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology 2002; 62:33-38.
14. Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10:943-947.
15. Popa IE, Stewart K, Smith FP et al. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung cancer. Cancer 2002; 95:1714-1719.
16. Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001; 33:277-287.
17. Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62:2-8.
18. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13:286-292.
19. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-1219.
20. Hainsworth JD, Burris HA III, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500-3505.
21. Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Ann Oncol 2001; 12:1393-1398.
22. Kornek GV, Haider K, Kwasny W, et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 2002; 8:1051-1056.
23. Palmeri S, Vaglica M, Accurso V, et al. Weekly docetaxel (doc) + gemcitabine (gem) as first line therapy for advanced breast cancer (ABC): a multicenter phase II study. Proc Am Soc Clin Oncol 2002; 21:45b (Abstract #1991).
24. Pelegri A, Calvo L, Mayordomo JI, et al. Gemcitabine and docetaxel given every 2 weeks as first-line therapy for metastatic breast cancer (MBC): results of a GEICAM phase II study. Proc Am Soc Clin Oncol 2002; 21:35b (Abstract #1950).
25. Fountzilas G, Nicolaides C, Bafaloukos D, et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000; 18:503-509.
26. Laufman L, Spiridonidis CH, Pritchard J, et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 2001; 12:1259-1264.
27. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 1999; 10:211-215.